

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 1/14/1954
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

PD-L1 22C3 by Immunohistochemistry, with Interpretation

ARUP test code 3017615

Adequacy of Specimen	Adequate
PD-L1 Client Block ID	ANAS24-13956 1
PDL1 Tissue Source	L Axillary mass
PDL1 TEST	CPS

PD-L1 22C3 by IHC With Combined Positive Score (CPS) Interpretation, Pembrolizumab (KEYTRUDA)

ARUP test code 3017681

Combined Positive Score	< 10
PDL1 22C3 IHC Result	No Expression Controls were run and performed as expected. This result has been reviewed and approved by [REDACTED]

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

INTERPRETIVE INFORMATION: PDL1 22C3 Combined Positive Score

PD-L1 22C3 by IHC with interpretation is an FDA-approved immunohistochemical assay using monoclonal mouse anti-PD-L1, clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) tissue using the EnVision FLEX visualization system on Autostainer Link 48 in gastric, esophageal, or GEJ adenocarcinomas, cervical carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and triple-negative breast cancer.

PD-L1 protein expression is determined by using combined positive score (CPS), which is the number of PD-L1 staining cells (tumor cells showing partial or complete linear membrane staining greater than or equal to 1+ plus lymphocytes and macrophages within tumor nests and adjacent supporting stroma, showing partial or complete linear membranous staining and/or cytoplasmic staining greater than or equal to 1+) divided by the total number of viable tumor cells, multiplied by 100. The table below summarizes how CPS is used to assess PD-L1 expression in certain tumor types.

Primary Tumor Type:
Gastric/Esophageal/GEJ Adenocarcinoma, Head/Neck Squamous Cell Carcinoma, Cervical Cancer
PD-L1 Expression Cutoff:
CPS <1: No PD-L1 expression
CPS ≥1: PD-L1 expression

Primary Tumor Type:
Triple-Negative Breast Cancer, Esophageal Squamous Cell Carcinoma
PD-L1 Expression Cutoff:
CPS <10: No PD-L1 expression
CPS ≥10: PD-L1 expression

The specimen submitted for testing must contain at least 100 viable, invasive tumor cells to be considered adequate for evaluation. This assay is indicated as an aid in identifying gastric, esophageal, or GEJ adenocarcinoma, cervical carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and triple-negative breast cancer in patients considered for treatment with pembrolizumab (KEYTRUDA). Please refer to the full prescribing information for tumor-specific indications and PD-L1 expression level cutoff.

Submission of slides that have been oven baked is not recommended as staining may be affected by overbaking or prolonged time between baking and staining. The use of this assay on decalcified tissues has not been validated and is not recommended. Testing on specimens fixed in any fixative other than 10 percent neutral buffered formalin has not been validated and is not recommended.

Controls were run and performed as expected.

Adequacy of Specimen	Adequate
PD-L1 Client Block ID	ANAS24-13956 1
PDL1 Tissue Source	L Axillary mass

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Combined Positive Score	24-131-152950	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PDL1 22C3 IHC Result	24-131-152950	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Adequacy of Specimen	24-131-152950	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Adequacy of Specimen	24-131-152950	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PD-L1 Client Block ID	24-131-152950	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PD-L1 Client Block ID	24-131-152950	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PDL1 Tissue Source	24-131-152950	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PDL1 Tissue Source	24-131-152950	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
PDL1 TEST	24-131-152950	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 24-131-152950
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 3 | Printed: 2/12/2025 2:43:34 PM
4848